Who
Robert Lorne Hopfner
Director
Company insider
Files Form 4 as: Director, Rallybio; Director and 10% owner, Evommune; Director and 10% owner, Inozyme Pharma; Director, Vaxcyte.
In numbers
- Trades disclosed
- 98
- Buys
- 11
- Sells
- 21
- Bought
- $25.2M
- Sold
- $22.0M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 11 Jun 2020
- Last trade
- 12 Oct 2026
- Last filed
- 14 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 14 Oct 2026 | RLYB RallybioBiotechnology | SEC FORM 4 Code M | $70K9,196 at $7.60 | filing |
| 12 Oct 2026filed 14 Oct 2026 | RLYB RallybioBiotechnology | SEC FORM 4 Code M | $8,4783,562 at $2.38 | filing |
| 12 Oct 2026filed 14 Oct 2026 | RLYB RallybioBiotechnology | SEC FORM 4 Code M | $32K2,062 at $15.28 | filing |
| 12 Oct 2026filed 14 Oct 2026 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code M | $5,1509,196 at $0.56 | filing |
| 12 Oct 2026filed 14 Oct 2026 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code M | —3,562 at $0.00 | filing |
| 12 Oct 2026filed 14 Oct 2026 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code M | —2,062 at $0.00 | filing |
| 19 Dec 2025filed 22 Dec 2025 | EVMN EvommuneBiotechnology | SEC FORM 4 Bought | $17K1,000 at $17.35 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —25,790 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —7,145,647 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,572,816 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,582,243 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —7,230,283 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,895,260 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,104,740 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —313,571 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —313,571 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,508,575 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN EvommuneBiotechnology | SEC FORM 4 Code C | —3,026 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN EvommuneBiotechnology | SEC FORM 4 Code C | —1,441,032 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN EvommuneBiotechnology | SEC FORM 4 Code C | —1,632,441 | filing |
News
Evommune (NYSE:EVMN) Stock Bumped Up to "Hold" by UBS GroupEVMN · tickerreport.com · 14 Oct 2026Evommune (NYSE:EVMN) Upgraded at UBS GroupEVMN · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Robert Lorne Hopfner; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.